Hai cercato la traduzione di neinferiornost da Sloveno a Inglese

neinferiornost sevelamerijevega karbonata so določili v 12. tednu.
non-inferiority to sevelamer carbonate was determined at week 12.

sklepi potrjujejo neinferiornost ne glede na metodo analize.
conclusions supported non-inferiority regardless of analysis method.

neinferiornost sevelamerijevega karbonata je bila ugotovljena v 12. tednu.
non-inferiority to sevelamer carbonate was determined at week 12.

0,89 (0,70, 1,13) vrednost p < 0,0001 (neinferiornost)
0.89 (0.70, 1.13) p-value < 0.0001 (non-inferiority)

Študija je bila zasnovana tako, da bi pokazala neinferiornost zdravila sancuso v primerjavi s peroralnim granisetronom.
the study was designed to show non-inferiority of sancuso to oral granisetron.

cilj študije je bil dokazati neinferiornost zdravila spectrila v primerjavi z referenčno asparaginazo e. coli glede primarnega končnega opazovanega dogodka.
the objective of the study was to demonstrate the non-inferiority of spectrila to the reference e. coli-asparaginase with regard to the primary endpoint.

preskušanje je dokazalo neinferiornost zdravila mabthera v primerjavi s ciklofosfamidom glede popolne remisije po 6 mesecih (preglednica 14).
the trial demonstrated non-inferiority of mabthera to cyclophosphamide for complete remission (cr) at 6 months (table 14).

ocenjeni učinki zdravljenja na mgk so bili podobni pri obeh učinkovinah, vendar načrt preskušanja ni bil dovolj robusten, da bi lahko potrdili neinferiornost zoledronske kisline.
estimated treatment effects on bmd were similar, but the trial design was not sufficiently robust to establish non-inferior efficacy for zoledronic acid.

f) interval zaupanja, ki je v celoti nad -10 %, kaže na neinferiornost zdravila eylea v primerjavi z ranibizumabom
f) a confidence interval lying entirely above -10% indicates a non-inferiority of eylea to ranibizumab

neinferiornost zdravila abilify maintena v primerjavi z peroralnim aripiprazolom 10–30 mg podpirajo tudi rezultati lestvice pozitivnih in negativnih simptomov (panss).
further, the non-inferiority of abilify maintena compared to oral aripiprazole 10-30 mg is supported by the results of the analysis of the positive and negative syndrome scale score (panss).

glede na agregirane podatke o vseh testiranih odmerkih v tej študiji je zdravilo cerdelga izpolnilo v študiji postavljena merila za neinferiornost pri vzdrževanju stabilnosti bolnikov v primerjavi z zdravilom cerezyme (imigluceraza).
based on the aggregate data from all doses tested in this study, cerdelga met the criteria set in this study to be declared non-inferior to cerezyme (imiglucerase) in maintaining patient stability.

farmakokinetični rezultati za eno od primarnih končnih ciljev, najnižjo koncentracijo pred 8. ciklom, so pokazali neinferiornost subkutane oblike zdravila herceptin v primerjavi z intravensko obliko zdravila herceptin, prilagojeno glede na telesno maso.
the pharmacokinetic results for the co primary endpoint, ctrough pre dose cycle 8, showed non-inferiority of the herceptin subcutaneous compared to the herceptin intravenous dose adjusted by body weight.

po prvih 12 tednih se je zdravljenje s kombinacijo fenofibrata 145 mg in simvastatina 20 mg izkazalo za učinkovitejše od zdravljenja s simvastatinom 40 mg pri znižanju tg in povišanju hdl-holesterola, vendar ni izpolnjevalo meril za neinferiornost pri ldl-holesterolu.
after the first 12 weeks of treatment, the combination of fenofibrate 145 mg and simvastatin 20 mg showed superiority over simvastatin 40 mg for tg reduction and hdl-c increase but did not meet the criteria for non-inferiority on ldl-c.

v populaciji, ki je bila primerna glede na protokol raziskave, je bila v celokupni primerjavi glede na preživetje brez napredovanja bolezni in celokupno preživetje dokazana neinferiornost skupin, ki so se zdravile po shemi xelox, v primerjavi s skupinami, ki so se zdravile po shemi folfox-4.
non-inferiority of the xelox-containing arms compared with the folfox-4-containing arms in the overall comparison was demonstrated in terms of progression-free survival and overall survival in the eligible per-protocol population.